Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...

Bain Capital is on the cusp of signing a deal to buy UK broker Jensten from private equity (PE) firm Livingbridge, Insurance ...

Saint Louis, MO, July 2025 – ButcherJoseph & Co. (“ButcherJoseph”) a boutique investment banking firm specializing in ESOPs and strategic corporate finance solutions, is pleased to welcome Thomas ...

"If we are getting creative, a possible claim would be for defamation," an attorney exclusively tells Page Six.

Building on Waystar's track record of successful M&A execution and synergy realization, Waystar expects the acquisition of Iodine to be immediately accretive to gross margin and adjusted EBITDA margin ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

American private investment firm Bain Capital is on the verge of acquiring a significant stake in Manappuram Finance, one of Kerala’s leading gold loan providers, in a deal valued at ...

BAIN CAPITAL SPECIALTY FINANCEDL-NOTES 2025 (25/30) (US05684BAD91) - All master data, key figures and real-time diagram.